Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer-Reference-Cited by-同舟云学术

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer

Published:2021-03-04 Issue:3 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Chuai Yunhai¹²,Rizzuto Ivana³,Zhang Xia¹⁴,Li Ying¹⁴,Dai Guanghai¹⁴,Otter Sophie J⁵,Bharathan Rasiah⁶,Stewart Alexandra⁵,Wang Aiming¹²

Affiliation:

1. Chinese PLA General Hospital, Medical School of Chinese PLA; Beijing China

2. Department of Obstetrics and Gynaecology; Sixth Medical Centre, Chinese PLA General Hospital; Beijing China

3. Department of Gynaecological Oncology; Royal Brisbane and Women’s Hospital; Brisbane Australia

4. Department of Oncology; Fifth Medical Centre, Chinese PLA General Hospital; Beijing China

5. Oncology; Royal Surrey County Hospital; Guildford UK

6. Department of Gynaecological Oncology; University Hospitals of Leicester NHS Trust, Leicester General Hospital; Leicester UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference164 articles.

1. A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage Chinese Clinical Trial Registry

2. Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study;Guo;Medicine,2020

3. A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced/recurrent disease EU Clinical Trials Register

4. A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC);Monk;Journal of Clinical Oncology,2009

5. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer;Monk;Journal of Clinical Oncology,2010

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anlotinib inhibits cervical cancer cell proliferation and invasion by suppressing cytokine secretion in activated cancer-associated fibroblasts;Frontiers in Oncology;2024-08-13

2. New Investigational Drug’s Targeting Various Molecular Pathways for Treatment of Cervical Cancer: Current Status and Future Prospects;Cancer Investigation;2024-07-05

3. Protective effect of quercetin on lipopolysaccharide‑induced miscarriage based on animal experiments and network pharmacology;Molecular Medicine Reports;2024-04-10

4. Predictors for the Development of Thromboembolic Events in Cancer Patients Treated with Bevacizumab, Ramucirumab, and Aflibercept: A Single-Institution Retrospective Analysis;Oncology;2024

5. A novel nomogram and risk stratification for early metastasis in cervical cancer after radical radiotherapy;Cancer Medicine;2023-11-23